Russian Health Ministry Opposes Ban on E-Liquid Sales

Regulations by 2FIRSTS.ai
Nov.24.2023
Russian Health Ministry Opposes Ban on E-Liquid Sales
Russia's health ministry opposes a ban on the sale of e-liquids containing nicotine, citing potential infringement on citizens' health protection law.

According to a report by the Russian news agency TASS on November 24th, the Russian Ministry of Health has stated that it does not support a ban on the sale of e-liquids containing and not containing nicotine.

 

The department's submitted motion to withdraw the bill draft argues that it could potentially violate the concept of the Citizen Health Protection Act and result in legal conflicts and ambiguous interpretations.

 

According to reports, the Ministry of Health has also pointed out that by 2023, the estimated tax revenue from the production and import of nicotine-containing e-liquids in Russia will be 3.6 billion rubles.

 

The department predicts that tax revenues will increase in the coming years, reaching 12.1 billion, 12.6 billion, and 13.1 billion rubles in 2024, 2025, and 2026 respectively.

 

The Ministry of Health believes that if retail is banned, it will result in a loss of over 12 billion rubles (CNY 964 million) in tax revenue annually, with no clear sources for compensation at present.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Altria’s Nicotine Pouch Rollout in the U.S.: On! PLUS May Launch on October 14, Not Yet FDA-Approved
Altria’s Nicotine Pouch Rollout in the U.S.: On! PLUS May Launch on October 14, Not Yet FDA-Approved
Altria’s new nicotine pouch On! PLUS™ is slated to launch in the U.S. on October 14, debuting in North Carolina, Texas, and Florida. The product uses NICOSILK™ technology and will offer multiple nicotine strengths. FDA approval has not yet been granted, but Helix says it is proceeding in line with compliance requirements.
Oct.11 by 2FIRSTS.ai
Russian Lawmaker Sounds Alarm as Teenage Vaping Surges—Female Use Overtakes Male
Russian Lawmaker Sounds Alarm as Teenage Vaping Surges—Female Use Overtakes Male
Russia’s Chair of the State Duma Committee on Youth Policy warns that among 11–14-year-olds, girls now vape at higher rates than boys, a trend he calls “deeply concerning.” He says the spread of nicotine products—especially e-cigarettes—among minors poses a public health risk and warrants continued policy-level interventions.
Oct.17 by 2FIRSTS.ai
Product | FASTA Unveils New U.S. Offering, Citing “Made in USA” Status and Texas Compliance
Product | FASTA Unveils New U.S. Offering, Citing “Made in USA” Status and Texas Compliance
FASTA has launched a new disposable, the FASTA ALIEN 51K, on U.S. online channels. Retailer Mi-Pod describes the product as “assembled and filled in the U.S.” and labels it as compliant with Texas e-cigarette registration requirements. The ALIEN 51K is now available via Mi-Pod and Vaping, with a suggested retail price of about $19.99.
Nov.12 by 2FIRSTS.ai
Philip Morris International and Swedish Match Win Collective Lawsuit Over Zyn Nicotine Pouches
Philip Morris International and Swedish Match Win Collective Lawsuit Over Zyn Nicotine Pouches
In a recent victory, Philip Morris International and Swedish Match won a lawsuit concerning their product Zyn's pricing.
Sep.25 by 2FIRSTS.ai
Product | 2× “2+10” configuration, rated 36,000 puffs — VOZOL launches NEON PLUG MAX
Product | 2× “2+10” configuration, rated 36,000 puffs — VOZOL launches NEON PLUG MAX
VOZOL has listed a new product, NEON PLUG MAX, on its official website, featuring dual 2 ml prefilled pods and dual 10 ml refill bottles (24 ml total), a claimed maximum of 36,000 puffs, and two-flavour switching. The device was previously shown at InterTabac 2025 and was listed by the UK MHRA in March 2025; however, as of publication it was not yet available on overseas retail sites.
Oct.22 by 2FIRSTS.ai
Smoore International's subsidiary, Transcend Biopharma, has its ANDA accepted by the FDA, potentially granting it 180 days of market exclusivity
Smoore International's subsidiary, Transcend Biopharma, has its ANDA accepted by the FDA, potentially granting it 180 days of market exclusivity
Smoore International announced that the U.S. FDA has accepted the Abbreviated New Drug Application (ANDA) for its Breo® Ellipta® 100/25 generic drug, submitted by its wholly-owned subsidiary, Transpire Bio. Transpire Bio stated that if approved, it is expected to receive 180 days of market exclusivity. In the United States, Breo® Ellipta® is already approved for the maintenance treatment of asthma and chronic obstructive pulmonary disease (COPD).
Sep.25 by 2FIRSTS.ai